Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human amniotic epithelial cells (IPMCH)
- Development stage
- Unknown
- Lead developer
- Shanghai iCELL Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial
01
Overview
Human amniotic epithelial cells (hAECs) are an investigational cell therapy developed by the International Peace Maternity and Child Health Hospital (IPMCH) for the treatment of primary ovarian insufficiency (POI) and premature ovarian failure (POF). Derived from the human amniotic membrane of the placenta, hAECs possess stem-cell-like properties, including low immunogenicity and multi-lineage differentiation potential. The therapy is administered via bilateral ovarian artery infusion, allowing the cells to migrate to the injured ovarian tissue. Once implanted, hAECs work by inhibiting the apoptosis of granulosa cells, promoting angiogenesis to restore blood flow, and improving the overall ovarian microenvironment (niche). Phase 1 clinical trial results have demonstrated that the transplantation is safe, well-tolerated, and may temporarily improve hormone levels, ovarian size, and menopausal symptoms in patients.
- Other names
- hAECThuman amniotic epithelial cells transplantationhuman amniotic epithelial cells-International Peace Maternity and Child Health Hospital-primary ovarian insufficiency
Beyond the preview
Go deeper on human amniotic epithelial cells (IPMCH).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human amniotic epithelial cells (IPMCH).